Posts

Medical Applications of Ketamine & Common Misconceptions with Christi Myers, Flow Integrative

Medical Applications of Ketamine & Common Misconceptions with Christi Myers, Flow Integrative

In this episode, Christi provides insight into how ketamine impacts people's physical and mental health. She goes into the comparison of ketamine's effects compared to other psychedelics and how...
Examining Ketamine-Assisted Psychotherapy with Myriam Barthes, Journey Clinical

Examining Ketamine Therapy with Myriam Barthes, Journey Clinical

In today’s episode, Myriam describes the impact of ketamine on the mind and the body, and specifically how ketamine therapy compares to other psychedelic-assisted therapies.

Psychedelic Business Spotlight – June 3

,
This week in psychedelic business news: Cybin moves towards clinical trials; Braxia releases data on treating depression with psilocybin; Clearmind files for a new patent; and much more!

Psychedelic Business Spotlight – May 13

,
This week in psychedelic business news: Beckley Retreats set launch; another shark swims into the psychedelics industry; and MindMed shares promising LSD study results.
Shutterstock

Elon Musk Excites Psychedelic Industry CEOs with This Tweet

,
This is one of the billionaire's most explicit acknowledgments of the power of psychedelics for mental health applications.
Shutterstock

Why Field Trip Health Is Dividing in Two — and What This Means for Investors

,
Field Trip Health plans to split into two independent, publicly traded companies: Field Trip Health and Wellness and Reunion Neuroscience.
3 Most Promising Psychedelics for Mental Health BreakthroughsShutterstock

3 Most Promising Psychedelics for Mental Health Breakthroughs

,
Psychiatrist, researcher, and CEO of Zylorion Health, Dr. Peter Silverstone, ranks psychedelic medicines based on their potential to revolutionize mental health treatment.
5 Most Important Psychedelic Clinical Trials of 2022Shutterstock

5 Most Important Psychedelic Clinical Trials in 2022

Here's why we think MAPS’ second Phase 3 MDMA trial is the most important psychedelic study of 2022, and 4 more that may have huge impacts.
Ketamine Study Suggests the Psychedelic Could Treat Parkinson's DiseaseShutterstock

Ketamine Study Suggests the Psychedelic Could Treat Parkinson’s Disease

PharmaTher evaluates safety, tolerability and efficacy of low-dose ketamine infusion for treatment of LID in Parkinson’s Disease patients.
Psychedelic Business Spotlight - March 18

Psychedelic Business Spotlight – March 18

,
This week in psychedelic business news: A psychedelics company folds; Ketamine Wellness Centers expand; Nova Mentis funds psilocybin studies.